298 patents
Page 9 of 15
Utility
Sustained-release Dosage Forms of Ruxolitinib
6 May 21
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
Filed: 16 Nov 20
Utility
Salts of 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE and Processes Related to Preparing the Same
6 May 21
The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Lingkai Weng, Lei Qiao, Jiacheng Zhou, Pingli Liu, Yongchun Pan
Filed: 8 Sep 20
Utility
Biomarkers for Graft-versus-host Disease
29 Apr 21
Biomarkers are provided that are predictive of a subject's responsiveness to a JAK inhibitor.
Michael D. Howell, Sherry Owens, Michael A. Pratta
Filed: 8 Oct 20
Utility
Biomarkers for Graft-versus-host Disease
29 Apr 21
Biomarkers are provided that are predictive of a subject's responsiveness to a JAK inhibitor.
Michael D. Howell, Sherry Owens, Michael A. Pratta
Filed: 8 Oct 20
Utility
Use of JAK1 Inhibitors for the Treatment of Cutaneous Lupus Erythematosus and Lichen Planus (LP)
22 Apr 21
The present application provides methods of treating a disease selected from cutaneous lupus erythematosus (CLE) and Lichen planus (LP) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a JAK1 selective inhibitor, or a pharmaceutically acceptable salt thereof.
Paul Smith, Jörg Wenzel
Filed: 16 Oct 20
Utility
Bicyclic Heterocycles As FGFR Inhibitors
22 Apr 21
Artem Shvartsbart, Jeremy Roach, Wenqing Yao
Filed: 15 Oct 20
Utility
Heterocyclic Compounds As Immunomodulators
22 Apr 21
Zhiyong Yu, Liangxing Wu, Wenqing Yao
Filed: 30 Dec 20
Utility
Heterocyclic Compounds As Immunomodulators
22 Apr 21
Liangxing Wu, Kaijiong Xiao, Wenqing Yao
Filed: 29 Dec 20
Utility
Carboxamide Compounds and Uses Thereof
1 Apr 21
Oleg Vechorkin, Jun Pan, Alexander Sokolsky, Evan Styduhar, Qinda Ye, Wenqing Yao
Filed: 9 Sep 20
Utility
Bicyclic Heterocycles As FGFR Inhibitors
1 Apr 21
Oleg Vechorkin, Hai Fen Ye, Wenqing Yao
Filed: 30 Sep 20
Utility
PYRIDO[3,2-D]PYRIMIDINE Compounds As Immunomodulators
1 Apr 21
Jingwei Li, Liangxing Wu, Wenqing Yao
Filed: 29 Sep 20
Utility
Treatment of B-cell Malignancies by a Combination Jak and PI3K Inhibitors
1 Apr 21
This invention relates to methods of treating B-cell malignancies using a combination of inhibitors of JAK1 and/or JAK2 and inhibitors of PI3Kδ.
Peggy A. Scherle, Xuesong Liu
Filed: 12 May 20
Utility
Amorphous Solid Form of a Bet Protein Inhibitor
18 Mar 21
The present invention relates to an amorphous solid form of (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, and processes for its preparation, which is an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and is useful in the treatment of various diseases such as cancer.
Shili Chen, William Frietze, Zhongjiang Jia, Pingli Liu, Jiacheng Zhou
Filed: 19 Nov 20
Utility
JAK1 Inhibitors for the Treatment of Myelodysplastic Syndromes
11 Mar 21
This invention relates to JAK1 selective inhibitors, particularly pyrrolo[2,3-d]pyrimidine and pyrrolo[2,3-b]pyridine derivatives, and their use in treating myelodysplastic syndromes (MDS).
Krishna Vaddi
Filed: 3 Apr 20
Utility
Ruxolitinib Formulation for Reduction of Itch In Atopic Dermatitis
11 Mar 21
This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.
Michael Kuligowski, Kang Sun, Michael Howell, May Grace E. Venturanza, Jim Lee
Filed: 4 Sep 20
Utility
Triazolopyrimidines As A2A / A2B Inhibitors
4 Mar 21
Heeoon Han, Le Zhao, Wenqing Yao, Xiaozhao Wang
Filed: 25 Aug 20
Utility
Imidazolyl Pyrimidinylamine Compounds As CDK2 Inhibitors
18 Feb 21
The present application provides imidazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Qinda Ye, Jingwei Li, Ken Mukai, Brandon Smith, Liangxing Wu, Wenqing Yao, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
Filed: 13 Aug 20
Utility
Salts of a PD-1/PD-L1 Inhibitor
11 Feb 21
The present invention relates to salt forms of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3′-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, including methods of preparation thereof, where the compound is useful in the treatment of various diseases including infectious diseases and cancer.
Zhongjiang Jia, Pingli Liu, David J. Meloni, Yongchun Pan, Yongzhong Wu, Jiacheng Zhou, Qun Li
Filed: 7 Aug 20
Utility
Solid Forms of an HPK1 Inhibitor
11 Feb 21
The present invention relates to salt forms of the hematopoietic progenitor kinase 1 (HPK 1) inhibitors N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-5-fluorophenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide and N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-4-(4-cyanopyridin-3-yl)phenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide, including methods of preparation thereof, where the compounds are useful in the treatment of HPK1 mediated diseases such as cancer.
Zhongjiang Jia, William Frietze
Filed: 5 Aug 20
Utility
1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase
4 Feb 21
The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu, Jiacheng Zhou, Qiyan Lin, Lingkai Weng, Tai-Yuen Yue, Pingli Liu
Filed: 15 Apr 20